Monthly Archives: March 2018

http://www.lslog.com/under-fire-for-5-deaths-of-patients-taking-hemlibra-roche-spills-details/Under fire for 5 deaths of patients taking Hemlibra, Roche spills details

Under fire for 5 deaths of patients taking Hemlibra, Roche spills details

Under fire for 5 deaths of patients taking Hemlibra, Roche spills details Despite Roche’s insistence that the deaths of five patients taking its Hemlibra for hemophilia were not related to […]

http://www.lslog.com/boehringer-ingelheim-taps-facebook-live-to-spread-scleroderma-awareness/Boehringer Ingelheim taps Facebook Live to spread scleroderma awareness

Boehringer Ingelheim taps Facebook Live to spread scleroderma awareness

Boehringer Ingelheim taps Facebook Live to spread scleroderma awareness Boehringer Ingelheim is looking to expand its compound nintedanib to treat some scleroderma patients. And in preparation, it’s looking to expand […]

http://www.lslog.com/lilly-seeks-to-quickly-advance-and-if-needed-kill-novel-drugs-to-avoid-pile-on-effect-in-hot-targets/Lilly seeks to quickly advance—and if needed kill—novel drugs to avoid ‘pile-on effect’ in hot targets

Lilly seeks to quickly advance—and if needed kill—novel drugs to avoid ‘pile-on effect’ in hot targets

Lilly seeks to quickly advance—and if needed kill—novel drugs to avoid ‘pile-on effect’ in hot targets Eli Lilly is doubling down on novel mechanisms of action to steer clear of […]

http://www.lslog.com/cash-reserves-running-low-at-kempharm/Cash reserves running low at KemPharm

Cash reserves running low at KemPharm

Cash reserves running low at KemPharm Money is getting tight at KemPharm, with its liquid cash reserves—currently around $48.5 million—not expected to last through the first quarter of 2019. Source: […]

http://www.lslog.com/gene-therapy-could-promote-healing-in-brain-spinal-cord-injuries/Gene therapy could promote healing in brain, spinal cord injuries

Gene therapy could promote healing in brain, spinal cord injuries

Gene therapy could promote healing in brain, spinal cord injuries Switching on the LZK gene in mice with spinal cord injuries resulted in a smaller scar, which UT Southwestern researchers […]

http://www.lslog.com/relax-celgene-investors-the-situation-isnt-as-bad-as-you-think-analyst/Relax, Celgene investors. The situation isn't as bad as you think: analyst

Relax, Celgene investors. The situation isn't as bad as you think: analyst

Relax, Celgene investors. The situation isn’t as bad as you think: analyst Celgene’s stock has taken a beating in recent months, thanks to a string of bad news. But the […]

http://www.lslog.com/teva-wont-owe-235m-penalty-in-coreg-carve-out-fight-with-glaxosmithkline/Teva won't owe $235M penalty in Coreg 'carve-out' fight with GlaxoSmithKline

Teva won't owe $235M penalty in Coreg 'carve-out' fight with GlaxoSmithKline

Teva won’t owe 5M penalty in Coreg ‘carve-out’ fight with GlaxoSmithKline Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 […]

http://www.lslog.com/denali-washu-team-clears-alzheimers-plaques-in-mice-by-targeting-a-faulty-apoe-gene/Denali-WashU team clears Alzheimer’s plaques in mice by targeting a faulty APOE gene

Denali-WashU team clears Alzheimer’s plaques in mice by targeting a faulty APOE gene

Denali-WashU team clears Alzheimer’s plaques in mice by targeting a faulty APOE gene A buildup of the beta-amyloid protein in the brain causes the formation of plaques in Alzheimer’s, but […]

http://www.lslog.com/redx-pauses-wnt-cancer-trial-after-first-patient-suffers-adverse-events/Redx pauses WNT cancer trial after first patient suffers adverse events

Redx pauses WNT cancer trial after first patient suffers adverse events

Redx pauses WNT cancer trial after first patient suffers adverse events Redx has hit pause on a phase 1/2a trial of its porcupine inhibitor after the first patient to receive […]

http://www.lslog.com/takeda-confirms-its-scoping-out-shire-for-a-gi-focused-buyout-bid-of-up-to-52b/Takeda confirms it's scoping out Shire for a GI-focused buyout bid of up to $52B

Takeda confirms it's scoping out Shire for a GI-focused buyout bid of up to $52B

Takeda confirms it’s scoping out Shire for a GI-focused buyout bid of up to B Shire has long been a popular buyout target, and it’s the latest to catch Takeda’s […]